Biocytogen, Sihuan accomplice to advance new weight reduction therapies
Biocytogen has entered right into a strategic partnership with Sihuan Pharmaceutical to advance novel therapies in a number of illness areas, together with weight reduction.
Underneath the settlement, Biocytogen’s totally human antibody discovery platform might be mixed with Sihuan Pharmaceutical’s drug growth, manufacturing and commercialization capabilities.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The collaboration will give attention to superior therapies throughout a number of illness areas, together with weight reduction, leveraging the businesses’ complementary capabilities to help growth and potential market development.
Biocytogen will leverage its built-in platforms, together with in vivo efficacy programs, humanized mouse fashions and an AI-based antibody discovery platform developed from actual human antibody sequences.
This strategy goals to help the event of recent antibody therapies and speed up promising molecules to medical and business phases.
Biocytogen President and CEO Dr. Yuelei Shen mentioned: “We’re happy to ascertain this strategic partnership with Sihuan Pharmaceutical.
“This collaboration will additional broaden our joint efforts in various illness areas and reveal sturdy trade recognition of our know-how platforms.”
Biocytogen focuses on the analysis and growth of antibody-based medicines utilizing gene modifying know-how.
The corporate has established a dual-engine platform that mixes a totally human antibody library with a portfolio of humanized mouse fashions to help international drug discovery and growth.
By its RenSuper Biologics sub-brand, it additionally provides a ready-made library of a couple of million totally human antibody sequences towards greater than 1,000 targets.
In January 2024, Biocytogen and Radiance Biopharma signed an unique choice and license settlement for a bispecific antibody-drug conjugate (BsADC).
